Physician profile
Michelle M Turner
NPI 1538109954
$93,718.41
in general payments reported to CMS, 2019-2025
20 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,160 · 2022: $1,028 · 2023: $52K · 2024: $17K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Travel and Lodging: $13K · Consulting Fee: $8,190 · Food and Beverage: $5,518 · Honoraria: $1,800 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,743.75 |
| Travel and Lodging | $13,174.38 |
| Consulting Fee | $8,190.00 |
| Food and Beverage | $5,517.91 |
| Honoraria | $1,800.00 |
| Education | $103.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $51,993.72 | 2021-2025 | Imfinzi, Tagrisso, Calquence |
| Mirati Therapeutics, INC. | $37,939.76 | 2023-2024 | Krazati |
| Merck Sharp & Dohme LLC | $1,337.18 | 2021-2024 | Keytruda |
| Janssen Biotech, INC. | $305.64 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Daiichi Sankyo INC. | $298.52 | 2023-2025 | Enhertu |
| Exelixis INC. | $257.35 | 2022-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $250.89 | 2021-2025 | |
| Amgen INC. | $248.21 | 2023-2024 | Imdelltra (Amg 757), Lumakras |
| Jazz Pharmaceuticals INC. | $233.23 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $139.32 | 2022-2023 | |
| Pfizer INC. | $138.15 | 2024 | |
| Incyte Corporation | $124.94 | 2024-2025 | |
| Genmab U.S., INC. | $121.65 | 2024 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $121.20 | 2022-2025 | |
| Gilead Sciences, INC. | $65.66 | 2023 | Trodelvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $53.49 | 2024 | Onivyde, Somatuline Depot |
| Novartis Pharmaceuticals Corporation | $27.36 | 2024 | |
| Lilly USA, LLC | $24.32 | 2024 | Jaypirca, Retevmo, Verzenio |
| Stemline Therapeutics INC. | $22.85 | 2024 | Orserdu |
| Genentech USA, INC. | $14.97 | 2024 | Gazyva, Venclexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.